Exploring the molecular mechanism of linagliptin in osteosarcoma cell lines for anti-cancer activity

Basit Öğe Kaydı
dc.authorid0000-0002-6424-7411en_US
dc.authorscopusid57366670900en_US
dc.authorwosidCJT-9277-2022en_US
dc.contributor.authorGök Yurttaş, Asiye
dc.contributor.authorDaşçı, Mustafa Fatih
dc.date.accessioned2023-07-09T14:03:48Z
dc.date.available2023-07-09T14:03:48Z
dc.date.issued2023en_US
dc.departmentFakülteler, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, Biyokimya Ana Bilim Dalıen_US
dc.description.abstractBackground: Finding new applications for widely used current drugs is a fast and effective technique for discovering new anticancer chemicals. Osteosarcoma (OS), the most prevalent form of bone cancer, has several side effects that significantly lower patients' quality of life. This study aims to systematically examine the anti-cancer activity of linagliptin (LG) in the osteosarcoma cell line Saos-2. Methods: MTT assays and flow cytometry were used to assess cell viability and apoptosis, respectively. qPCR array experiments were carried out to determine target gene expressions and explain the molecular mechanism of LG's action. Results: Linagliptin treatment significantly decreased the viability of Saos-2 cells and hFOB1.19 cells (p < 0.001). The treatment also induced increased apoptotic effects in both Saos-2 cells (p < 0.001) and hFOB1.19 cells (p < 0.05). qPCR assays were conducted to assess cancer pathway analysis after applying specific quantities of LG to Saos-2 and hFOB1.19 cells. Conclusion: The findings of this study demonstrate that LG inhibits the proliferation of Saos-2 cells and induces cell death. LG supports cell death by suppressing the expression of specific genes involved in cancer pathways.en_US
dc.identifier.citationGök Yurttaş, A., & Daşçı, M. F. (2023). Exploring the molecular mechanism of linagliptin in osteosarcoma cell lines for anti-cancer activity. Pathology Research and Practice, 248, pp. 1-6. https://doi.org/10.1016/j.prp.2023.154640en_US
dc.identifier.doi10.1016/j.prp.2023.154640en_US
dc.identifier.endpage6en_US
dc.identifier.issn0344-0338
dc.identifier.issn1618-0631
dc.identifier.pmidPMID: 37421842en_US
dc.identifier.scopus2-s2.0-85164317281en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.1016/j.prp.2023.154640
dc.identifier.urihttps://hdl.handle.net/20.500.13055/497
dc.identifier.volume248en_US
dc.identifier.wosWOS:001069619500001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynak.otherSCI-E - Science Citation Index Expandeden_US
dc.institutionauthorGök Yurttaş, Asiye
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofPathology Research and Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnti-Canceren_US
dc.subjectHFOB1.19en_US
dc.subjectLinagliptinen_US
dc.subjectOsteosarcomaen_US
dc.subjectQPCRen_US
dc.subjectSaos-2en_US
dc.titleExploring the molecular mechanism of linagliptin in osteosarcoma cell lines for anti-cancer activityen_US
dc.typeArticleen_US
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
Exploring the molecular mechanism of linagliptin in osteosarcoma cell lines for anti-cancer activity.pdf
Boyut:
1.05 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Biyokimya Ana Bilim Dalı Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu